Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 With a Parallel Optional Maximal Use Arm- in Treatment of RXLI or ARCI Ichthyosis in Subjects Aged >6

Next Previous
X
Search
Trial Profile

A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 With a Parallel Optional Maximal Use Arm- in Treatment of RXLI or ARCI Ichthyosis in Subjects Aged >6

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isotretinoin (Primary) ; Isotretinoin (Primary)
  • Indications Congenital ichthyosiform erythroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND
  • Sponsors LEO Pharma; Trex Wind-down

    • Most Recent Events

    • 21 Mar 2024 Status changed from recruiting to active, no longer recruiting.
    • 12 Mar 2024 PK results of 13 adolescent and adult participants with moderate to sever XLRI or ARCI in the Maximal Use Study Arm of the study, presented at the American Academy of Dermatology annual Meeting 2024
    • 11 Mar 2024 According to a LEO Pharma media release, the company presents preliminary results from the ASCEND trial in a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top